Transcode Therapeutics (RNAZ) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.70, -5.56% vs the prior close of $1.80.
- Volume 28.34K shares, 0.5x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
RNAZ slides 5.6% to $1.70. Closed at $1.70, -5.56% vs the prior close of $1.80. Day range $1.70–$1.86, opened at $1.83.
RNAZ daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — RNAZ slides 5.6% to $1.70
- Closed at $1.70, -5.56% vs the prior close of $1.80. Day range $1.70–$1.86, opened at $1.83.
- Volume was 28.34K shares, 0.5x its 50-day average of 62.39K — lighter than usual.
- Price is -21.8% vs its 50-day average ($2.17) and -73.7% vs its 200-day average ($6.45).
- 52-week range $1.52–$15.49; today's close sits at 1% of that range, 89.0% below the 52-week high.
Oct 15, 2026 — RNAZ jumps 4.0% to $1.80, 3 up days in a row
- Closed at $1.80, +4.05% vs the prior close of $1.73. Day range $1.71–$1.90, opened at $1.79.
- Volume was 35.00K shares, 0.6x its 50-day average of 61.86K — lighter than usual.
- Price is -19.1% vs its 50-day average ($2.23) and -72.2% vs its 200-day average ($6.48).
- 52-week range $1.52–$15.49; today's close sits at 2% of that range, 88.4% below the 52-week high.
- That makes 3 straight gains.
Oct 14, 2026 — RNAZ rises 3.0% to $1.73
- Closed at $1.73, +2.98% vs the prior close of $1.68. Day range $1.67–$1.82, opened at $1.74.
- Volume was 43.20K shares, 0.7x its 50-day average of 61.29K.
- Price is -23.9% vs its 50-day average ($2.27) and -73.4% vs its 200-day average ($6.50).
- 52-week range $1.52–$15.90; today's close sits at 1% of that range, 89.1% below the 52-week high.
Oct 13, 2026 — RNAZ jumps 3.1% to $1.68
- Closed at $1.68, +3.07% vs the prior close of $1.63. Day range $1.67–$1.78, opened at $1.67.
- Volume was 54.30K shares, 0.9x its 50-day average of 60.41K.
- Price is -27.9% vs its 50-day average ($2.33) and -74.3% vs its 200-day average ($6.53).
- 52-week range $1.52–$15.90; today's close sits at 1% of that range, 89.4% below the 52-week high.
Oct 12, 2026 — RNAZ slides 12.4% to $1.63
- Closed at $1.63, -12.37% vs the prior close of $1.86. Day range $1.63–$1.91, opened at $1.91.
- Volume was 31.90K shares, 0.5x its 50-day average of 60.38K — lighter than usual.
- Price is -31.5% vs its 50-day average ($2.38) and -75.1% vs its 200-day average ($6.55).
- 52-week range $1.52–$15.94; today's close sits at 1% of that range, 89.8% below the 52-week high.
Oct 9, 2026 — RNAZ jumps 8.8% to $1.86, a 1-month high
- Closed at $1.86, +8.77% vs the prior close of $1.71. Day range $1.74–$1.95, opened at $1.78.
- Volume was 84.10K shares, 1.4x its 50-day average of 58.90K.
- Price is -23.7% vs its 50-day average ($2.44) and -71.8% vs its 200-day average ($6.58).
- 52-week range $1.52–$15.94; today's close sits at 2% of that range, 88.3% below the 52-week high.
Oct 8, 2026 — RNAZ dips 2.8% to $1.71
- Closed at $1.71, -2.84% vs the prior close of $1.76. Day range $1.67–$1.80, opened at $1.80.
- Volume was 27.80K shares, 0.5x its 50-day average of 58.45K — lighter than usual.
- Price is -31.8% vs its 50-day average ($2.51) and -74.1% vs its 200-day average ($6.61).
- 52-week range $1.52–$20.99; today's close sits at 1% of that range, 91.9% below the 52-week high.
Oct 7, 2026 — RNAZ dips 1.1% to $1.76
- Closed at $1.76, -1.12% vs the prior close of $1.78. Day range $1.67–$1.79, opened at $1.78.
- Volume was 29.80K shares, 0.5x its 50-day average of 58.70K — lighter than usual.
- Price is -31.5% vs its 50-day average ($2.57) and -73.5% vs its 200-day average ($6.64).
- 52-week range $1.52–$20.99; today's close sits at 1% of that range, 91.6% below the 52-week high.
Oct 6, 2026 — RNAZ rises 1.1% to $1.78, 3 up days in a row
- Closed at $1.78, +1.14% vs the prior close of $1.76. Day range $1.71–$1.82, opened at $1.77.
- Volume was 47.20K shares, 0.8x its 50-day average of 58.24K.
- Price is -32.5% vs its 50-day average ($2.64) and -73.3% vs its 200-day average ($6.67).
- 52-week range $1.52–$20.99; today's close sits at 1% of that range, 91.5% below the 52-week high.
- That makes 3 straight gains.
Oct 5, 2026 — RNAZ jumps 12.1% to $1.76
- Closed at $1.76, +12.10% vs the prior close of $1.57. Day range $1.57–$1.87, opened at $1.65.
- Volume was 65.70K shares, 1.1x its 50-day average of 57.42K.
- Price is -35.0% vs its 50-day average ($2.71) and -73.8% vs its 200-day average ($6.71).
- 52-week range $1.52–$20.99; today's close sits at 1% of that range, 91.6% below the 52-week high.
Oct 2, 2026 — RNAZ rises 1.6% to $1.57
- Closed at $1.57, +1.62% vs the prior close of $1.54. Day range $1.54–$1.66, opened at $1.58.
- Volume was 15.50K shares, 0.3x its 50-day average of 57.38K — lighter than usual.
- Price is -43.8% vs its 50-day average ($2.79) and -76.7% vs its 200-day average ($6.74).
- 52-week range $1.52–$20.99; today's close sits at 0% of that range, 92.5% below the 52-week high.
RNAZ latest news & SEC filings
Every SEC filing by or about RNAZ in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.04 — Event that accelerates a debt obligation.
Sep 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 21, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 14, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$6.75M (prior year -$4.28M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$7.17 (prior year -$5.13) (loss widened vs Jun 30, 2025)
Aug 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 5, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 3, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.03 — Change to shareholder rights.
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
Jul 28, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 28, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 28, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 27, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 23, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade RNAZ
- Last results release: Apr 5, 2024 (8-K Item 2.02). Previous ones: Jan 16, 2024, Nov 14, 2023, Mar 31, 2023. Based on that rhythm, the next report is likely around Jul 5, 2024 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.45% (largest 12.4%). That is a volatile stock.
- Liquidity: about 56.13K shares (≈$95.42K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.70 vs a range of $1.52–$15.49 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:28 on May 15, 2025, 1:33 on Dec 4, 2024
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Oct 1, 2026; 8-K Sep 28, 2026; 8-K Sep 11, 2026.
- Share count: 16.93M shares outstanding (Aug 10, 2026), +1930.8% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
RNAZ market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.83 | 1.86 | 1.70 | 1.70 | 28.34K |
| Oct 15, 2026 | 1.79 | 1.90 | 1.71 | 1.80 | 35.00K |
| Oct 14, 2026 | 1.74 | 1.82 | 1.67 | 1.73 | 43.20K |
| Oct 13, 2026 | 1.67 | 1.78 | 1.67 | 1.68 | 54.30K |
| Oct 12, 2026 | 1.91 | 1.91 | 1.63 | 1.63 | 31.90K |
| Oct 9, 2026 | 1.78 | 1.95 | 1.74 | 1.86 | 84.10K |
| Oct 8, 2026 | 1.80 | 1.80 | 1.67 | 1.71 | 27.80K |
| Oct 7, 2026 | 1.78 | 1.79 | 1.67 | 1.76 | 29.80K |
| Oct 6, 2026 | 1.77 | 1.82 | 1.71 | 1.78 | 47.20K |
| Oct 5, 2026 | 1.65 | 1.87 | 1.57 | 1.76 | 65.70K |
| Oct 2, 2026 | 1.58 | 1.66 | 1.54 | 1.57 | 15.50K |
| Oct 1, 2026 | 1.67 | 1.74 | 1.52 | 1.54 | 16.70K |
| Sep 30, 2026 | 1.75 | 1.75 | 1.64 | 1.68 | 6.70K |
| Sep 29, 2026 | 1.73 | 1.81 | 1.60 | 1.63 | 11.00K |
| Sep 28, 2026 | 1.71 | 1.79 | 1.63 | 1.71 | 40.40K |
| Sep 25, 2026 | 1.60 | 1.70 | 1.60 | 1.69 | 14.80K |
| Sep 24, 2026 | 1.62 | 1.74 | 1.62 | 1.65 | 25.60K |
| Sep 23, 2026 | 1.84 | 2.39 | 1.62 | 1.68 | 421.00K |
| Sep 22, 2026 | 1.87 | 1.91 | 1.71 | 1.77 | 57.30K |
| Sep 21, 2026 | 1.67 | 1.97 | 1.67 | 1.76 | 66.20K |
About Transcode Therapeutics
Transcode Therapeutics (RNAZ) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BOSTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1829635.
RNAZ board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Elizabeth Czerepak | Director | Dec 22, 2025 |
| Thomas A Fitzgerald | Chief Financial Officer | Sep 11, 2026 |
| Jack E Stover | Director | Dec 22, 2025 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Thomas A Fitzgerald | Chief Financial Officer | Sep 11, 2026 |
| John A Tattory | Interim CFO | Sep 21, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
RNAZ financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-34.66M | -52.59 | $-19.52M |
| Dec 31, 2024 | — | $-16.75M | -1,336.63 | $-13.34M |
| Dec 31, 2023 | — | $-18.55M | -3,419.01 | $-18.07M |
| Dec 31, 2022 | — | $-17.56M | -1,082.79 | $-15.76M |
| Dec 31, 2021 | — | $-6.84M | -0.81 | $-5.27M |
Latest balance sheet: total assets $151.01M, total liabilities $12.65M, cash $8.38M (as of Jun 30, 2026).
RNAZ earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Apr 5, 2024 | 8-K Item 2.02 (results) | — |
| Jan 16, 2024 | 8-K Item 2.02 (results) | — |
| Nov 14, 2023 | 8-K Item 2.02 (results) | — |
| Mar 31, 2023 | 8-K Item 2.02 (results) | — |
| Feb 17, 2023 | 8-K Item 2.02 (results) | — |
| Feb 1, 2023 | 8-K Item 2.02 (results) | — |
| Nov 14, 2022 | 8-K Item 2.02 (results) | — |
| Aug 15, 2022 | 8-K Item 2.02 (results) | — |
| May 16, 2022 | 8-K Item 2.02 (results) | — |
| Apr 1, 2022 | 8-K Item 2.02 (results) | — |
| Nov 15, 2021 | 8-K Item 2.02 (results) | — |
| Aug 23, 2021 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on RNAZ
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.